Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination

<jats:sec><jats:title>Objective</jats:title><jats:p>Endoscopic mucosal biopsies of primary gastric cancers (GCs) are used to guide diagnosis, biomarker testing and treatment. Spatial intratumoural heterogeneity (ITH) may influence biopsy-derived information. We aimed to study ITH of primary GCs and matched lymph node metastasis (LN<jats:sub>met</jats:sub>).</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>GC resection samples were annotated to identify primary tumour superficial (PT<jats:sub>sup</jats:sub>), primary tumour deep (PT<jats:sub>deep</jats:sub>) and LN<jats:sub>met</jats:sub> subregions. For each subregion, we determined (1) transcriptomic profiles (NanoString ‘PanCancer Progression Panel’, 770 genes); (2) next-generation sequencing (NGS, 225 gastrointestinal cancer-related genes); (3) DNA copy number profiles by multiplex ligation-dependent probe amplification (MLPA, 16 genes); and (4) histomorphological phenotypes.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>NanoString profiling of 64 GCs revealed no differences between PT<jats:sub>sup1</jats:sub> and PT<jats:sub>sup2</jats:sub>, while 43% of genes were differentially expressed between PT<jats:sub>sup</jats:sub> versus PT<jats:sub>deep</jats:sub> and 38% in PT<jats:sub>sup</jats:sub> versus LN<jats:sub>met</jats:sub>. Only 16% of genes were differently expressed between PT<jats:sub>deep</jats:sub> and LN<jats:sub>met</jats:sub>. Several genes with therapeutic potential (eg <jats:italic>IGF1</jats:italic>, <jats:italic>PIK3CD</jats:italic> and <jats:italic>TGFB1</jats:italic>) were overexpressed in LN<jats:sub>met</jats:sub> and PT<jats:sub>deep</jats:sub> compared with PT<jats:sub>sup</jats:sub>. NGS data revealed orthogonal support of NanoString results with 40% mutations present in PT<jats:sub>deep</jats:sub> and/or LN<jats:sub>met</jats:sub>, but not in PT<jats:sub>sup</jats:sub>. Conversely, only 6% of mutations were present in PT<jats:sub>sup</jats:sub> and were absent in PT<jats:sub>deep</jats:sub> and LN<jats:sub>met</jats:sub>. MLPA demonstrated significant ITH between subregions and progressive genomic changes from PT<jats:sub>sup</jats:sub> to PT<jats:sub>deep</jats:sub>/LN<jats:sub>met</jats:sub>.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In GC, regional lymph node metastases are likely to originate from deeper subregions of the primary tumour. Future clinical trials of novel targeted therapies must consider assessment of deeper subregions of the primary tumour and/or metastases as several therapeutically relevant genes are only mutated, overexpressed or amplified in these regions.</jats:p></jats:sec>